This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Contracted by skin contact with freshwater containing infected snails — common in Sub-Saharan Africa. Avoid swimming, wading, or bathing in freshwater lakes and rivers in endemic areas. Seawater and chlorinated pools are safe. Screening after travel is recommended if exposed.
Parasitic disease caused by Schistosoma blood flukes, acquired through freshwater exposure. Affects over 250 million people worldwide, predominantly in Sub-Saharan Africa.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Itching | 65% | Mild | Early |
| Rash | 55% | Mild | Early |
| Fever | 60% | Moderate | Peak |
| Cough | 40% | Mild | Peak |
| Malaise | 50% | Mild | Peak |
| Myalgia | 40% | Mild | Peak |
| Urticaria | 35% | Mild | Peak |
| Arthralgia | 20% | Mild | Peak |
| Chills | 30% | Mild | Peak |
| Headache | 35% | Mild | Peak |
| Hematuria | 50% | Moderate | Late |
| Abdominal pain | 50% | Mild | Late |
| Dysuria | 40% | Mild | Late |
| Hepatomegaly | 35% | Moderate | Late |
| Bloody stool | 20% | Moderate | Late |
| Diarrhea | 35% | Mild | Late |
| Splenomegaly | 20% | Moderate | Late |
| Weight loss | 25% | Mild | Late |
| Fatigue | 55% | Mild | Any phase |
| Loss of appetite | 30% | Mild | Any phase |
Schistosomiasis (also known as bilharzia) is a chronic parasitic disease caused by trematode blood flukes of the genus Schistosoma. It is the second most socioeconomically impactful parasitic disease after malaria, affecting an estimated 240 million people in 78 countries, with approximately 11,700–200,000 deaths per year (GBD 2019 estimates ~11,700; older WHO estimates ~200,000) and over 700 million people at risk.
Three species cause the vast majority of human disease:
Schistosoma mansoni — intestinal/hepatic schistosomiasis (Africa, Middle East, South America)
Schistosoma haematobium — urogenital schistosomiasis (Africa, Middle East)
Schistosoma japonicum — intestinal/hepatic schistosomiasis (East Asia, Philippines)
The life cycle requires freshwater snails as intermediate hosts. Infected snails release free-swimming cercariae that penetrate human skin within minutes during contact with contaminated freshwater. Adult worms reside in mesenteric or vesical venous plexuses and can survive for 3-10 years (some reports up to 30 years).
Disease is primarily caused by the host immune response to schistosome eggs trapped in tissues, which provoke granulomatous inflammation and progressive fibrosis. Acute infection may cause cercarial dermatitis ("swimmer's itch") and Katayama fever. Chronic infection leads to hepatosplenic disease (S. mansoni, S. japonicum) or urogenital disease with increased risk of bladder cancer (S. haematobium — classified as a Group 1 carcinogen by IARC).
Praziquantel is the mainstay of treatment — a single oral dose achieves cure rates of 70-100%. Mass drug administration programs targeting school-age children are the primary control strategy.
Clinical Overview
Schistosomiasis is a neglected tropical disease of enormous public health importance, affecting predominantly impoverished communities in tropical and subtropical regions.
Key Clinical Facts:
Causative agents: S. mansoni, S. haematobium, S. japonicum (main species); S. mekongi, S. intercalatum, S. guineensis (regional importance)
Transmission: Skin penetration by cercariae in contaminated freshwater (rivers, lakes, irrigation canals, dams)
Intermediate host: Freshwater snails (Biomphalaria spp. for S. mansoni, Bulinus spp. for S. haematobium, Oncomelania spp. for S. japonicum)
Incubation: Cercarial dermatitis within hours; Katayama fever 2-8 weeks post-exposure; chronic disease over months to years
Global burden: ~240 million infected, ~700 million at risk, ~11,700-200,000 deaths/year (range reflects GBD 2019 vs older WHO estimates)
Treatment: Praziquantel 40-60 mg/kg (single dose), cure rate 70-100%
No licensed vaccine — several candidates in clinical trials
Disease Forms:
Special Significance:
WHO classifies S. haematobium infection as a Group 1 carcinogen (definite cause of bladder cancer)
Female genital schistosomiasis (FGS) affects an estimated 56 million women and girls, increasing HIV acquisition risk 3-4 fold
Schistosomiasis is a significant cause of anemia, malnutrition, and impaired cognitive development in children in endemic areas
Emergency Warning Signs
While schistosomiasis is typically a chronic disease, certain acute complications and advanced disease manifestations require urgent medical attention.
Acute Emergencies:
Massive hematemesis (vomiting large volumes of blood): Indicates esophageal variceal bleeding due to portal hypertension from hepatosplenic schistosomiasis. This is a life-threatening emergency requiring immediate intervention (endoscopic banding/sclerotherapy, blood transfusion, vasoactive drugs).
Acute abdomen: Severe abdominal pain, rigidity, and distension may indicate variceal rupture, bowel obstruction from massive polyposis, or intestinal perforation (rare).
Severe Katayama syndrome: High fever, respiratory distress (cough, wheeze, dyspnea), and severe systemic illness in a recently exposed traveler. Can be life-threatening if unrecognized.
Acute transverse myelitis: Sudden onset of lower limb weakness, sensory level, and urinary retention due to spinal cord egg granulomas (most common with S. mansoni). Constitutes a neurological emergency requiring immediate corticosteroids and praziquantel to prevent permanent paraplegia.
Neurological Warning Signs:
Sudden onset paraplegia or paraparesis (spinal cord involvement)
Seizures, altered consciousness, severe headache (cerebral involvement — more common with S. japonicum)
Focal neurological deficits
Cauda equina syndrome (lower limb weakness, saddle anesthesia, urinary/fecal incontinence)
Urological Warning Signs:
Gross hematuria with clots causing urinary retention
Flank pain with fever (indicates obstructive uropathy with secondary pyelonephritis)
Anuria (complete ureteral obstruction — bilateral or in a solitary kidney)
Chronic Disease Decompensation:
Progressive abdominal distension with ascites (portal hypertension)
Pedal edema, jaundice, spider nevi (hepatic decompensation — note: pure Symmers fibrosis usually preserves hepatocellular function; concurrent viral hepatitis B/C worsens prognosis)
Rectal prolapse (massive intestinal polyposis, particularly in children with S. mansoni)
In Travelers: Katayama syndrome may be misdiagnosed as many other febrile illnesses. Any traveler with eosinophilia, fever, and freshwater exposure in an endemic area should be evaluated for acute schistosomiasis.
Most common signs and symptoms
Symptom Presentation
Schistosomiasis symptoms vary by disease stage and the infecting species. Many chronically infected individuals in endemic areas are asymptomatic or paucisymptomatic despite carrying significant worm burdens.
1. Cercarial Dermatitis (Swimmer's Itch):
Occurs within minutes to hours of skin penetration by cercariae
Pruritic, erythematous, papular rash at the site of penetration
More prominent with non-human schistosome species (avian schistosomes common in temperate lakes)
Resolves spontaneously within 1-2 weeks
Often the first sign of infection in travelers
2. Acute Schistosomiasis (Katayama Syndrome):
Occurs 2-8 weeks after primary infection, coinciding with onset of egg production
Much more common in primary infections (travelers, non-immune individuals) than in residents of endemic areas
High fever (often >39°C), rigors, sweats
Nonproductive cough, wheeze (pulmonary infiltrates on chest X-ray)
Urticaria, angioedema
Hepatosplenomegaly with right upper quadrant pain
Marked eosinophilia (often >3000/uL)
Myalgia, arthralgia, headache, fatigue
Can be severe and occasionally fatal
Resolves over weeks but may persist for months if untreated
3. Chronic Intestinal Schistosomiasis (S. mansoni, S. japonicum):
Intermittent abdominal pain, particularly periumbilical or left lower quadrant
Bloody diarrhea (occult or visible blood)
Iron deficiency anemia
Fatigue, reduced exercise tolerance
Hepatomegaly (early) → hepatosplenomegaly (advanced)
Periportal (Symmers pipe-stem) fibrosis: Progressive fibrosis around portal vein branches, leading to portal hypertension
Ascites, esophageal varices with risk of variceal hemorrhage
S. japonicum typically causes more severe hepatic disease due to higher egg output
4. Chronic Urogenital Schistosomiasis (S. haematobium):
Hematuria — the hallmark symptom (often painless, terminal hematuria)
Dysuria, urinary frequency
Suprapubic discomfort
Hydronephrosis, hydroureter (ureteral stricture from egg granulomas)
Bladder fibrosis and calcification
Squamous cell carcinoma of the bladder (long-term complication)
Female genital schistosomiasis (FGS): Vulvar/vaginal lesions ("sandy patches"), pelvic pain, dyspareunia, irregular bleeding, infertility
Male genital schistosomiasis: Hematospermia, orchitis, prostatitis
Knowing the symptoms is the first step to a quick response.
Disease Course and Progression
Schistosomiasis follows a complex natural history from initial skin penetration through chronic organ damage over years to decades.
Exposure and Skin Penetration (Minutes):
Cercariae released from infected freshwater snails penetrate intact human skin within minutes
Each cercaria sheds its tail and transforms into a schistosomulum (immature worm)
Penetration may cause cercarial dermatitis (pruritic papular rash) within hours
Migration Phase (Weeks 1-4):
Schistosomula enter dermal venules and lymphatics, reaching the lungs within days
Passage through pulmonary capillaries (may cause transient cough/wheeze)
Migration to the portal system via systemic circulation
Maturation in intrahepatic portal veins over 4-6 weeks
Male and female worms pair (they live as mated pairs for their entire lifespan)
Egg Production Phase (Week 5-8 onwards):
Paired adult worms migrate to their species-specific venous plexus:
Female worms begin producing eggs (S. mansoni: ~300 eggs/day; S. japonicum: ~3,000 eggs/day; S. haematobium: ~200 eggs/day)
Some eggs penetrate vascular walls and pass through tissues to reach the intestinal or bladder lumen for excretion
Trapped eggs that fail to transit become lodged in tissues (liver, intestine, bladder, lungs, CNS), provoking granulomatous inflammation
Acute Phase — Katayama Syndrome (Weeks 2-8 post-exposure):
Hypersensitivity response to initial egg deposition and circulating immune complexes
More common and severe in primary infections (travelers, non-immune individuals)
Fever, eosinophilia, hepatosplenomegaly, urticaria, respiratory symptoms
Self-limiting over weeks to months
Chronic Phase (Months to Decades):
Progressive granulomatous inflammation and fibrosis around trapped eggs
Hepatosplenic disease: Periportal (Symmers) fibrosis → portal hypertension → esophageal varices → variceal hemorrhage
Urogenital disease: Bladder wall granulomas → fibrosis → calcification → obstructive uropathy → squamous cell carcinoma (decades)
Adult worms survive 3-10 years on average (reports of 30+ years)
Even after worm death, trapped eggs continue to provoke granulomatous responses
Without reinfection, egg excretion ceases within years as worms senesce
Resolution/Burnout: In some long-lived infections, a degree of immune modulation develops, with reduced granuloma size around older eggs. However, fibrosis persists and may progress even after worm death.
How this disease is identified
Diagnosis
Schistosomiasis diagnosis uses parasitological, immunological, and molecular methods. The choice of test depends on the clinical setting (endemic area screening vs. individual traveler diagnosis) and the phase of infection.
Parasitological Methods (Direct Detection):
Stool Microscopy (S. mansoni, S. japonicum):
Urine Microscopy (S. haematobium):
Tissue Biopsy:
Immunological Methods:
Point-of-Care Circulating Cathodic Antigen (POC-CCA) — Urine Test:
Serology (Antibody Detection):
Molecular Methods:
Imaging:
Abdominal ultrasound: WHO-standardized protocol for assessing hepatosplenic disease (liver fibrosis pattern, portal vein diameter, spleen size). The Niamey protocol is used for grading periportal fibrosis.
CT/MRI: For neuroschistosomiasis diagnosis (spinal cord or cerebral granulomas)
Cystoscopy and IVP/CT urogram: For assessing bladder pathology and upper tract obstruction in S. haematobium
Available treatment methods
Treatment and Management
The cornerstone of schistosomiasis treatment is praziquantel, which is effective against all human Schistosoma species. Treatment strategy depends on whether the infection is acute or chronic.
Praziquantel — First-Line Treatment:
S. mansoni and S. haematobium: 40 mg/kg in a single dose (or divided into two doses 4-6 hours apart)
S. japonicum and S. mekongi: 60 mg/kg divided into 2-3 doses over one day (higher egg burden)
Cure rate: 70-100% with a single treatment course
Egg reduction rate: >95% in most patients
Retreatment after 2-4 weeks may be needed if symptoms persist or eggs remain detectable
Side effects: generally mild and transient — nausea, abdominal pain, diarrhea, headache, dizziness. More common and intense with higher worm burdens.
Safe in pregnancy (WHO recommends treatment of pregnant women in endemic areas)
Important Note on Timing: Praziquantel is effective only against adult worms, not against immature schistosomula. In acute infections (Katayama syndrome), treatment should be given but may need to be repeated 6-8 weeks later to kill worms that were immature at the time of initial treatment.
Treatment of Acute Schistosomiasis (Katayama Syndrome):
Corticosteroids (prednisolone 1-2 mg/kg/day tapered over 2-3 weeks) — to control the hypersensitivity reaction
Praziquantel — given during the acute illness AND repeated at 6-8 weeks
Supportive care: antipyretics, hydration, bronchodilators if needed
Treatment of Neuroschistosomiasis:
Corticosteroids (high-dose dexamethasone or methylprednisolone) — URGENT to reduce inflammation and prevent permanent neurological damage
Praziquantel — given with steroid cover
Neurosurgical consultation for space-occupying lesions
Management of Advanced Hepatosplenic Disease:
Praziquantel kills adult worms and prevents further egg deposition but does not reverse established fibrosis
Portal hypertension management: non-selective beta-blockers, endoscopic variceal banding
Variceal hemorrhage: emergency endoscopy, blood transfusion, vasoactive agents (octreotide)
Surgical portosystemic shunts or TIPS for recurrent variceal bleeding
Management of Urogenital Complications:
Praziquantel for active infection
Ureteral stenting or surgical repair for obstructive uropathy
Bladder cancer surveillance (cystoscopy) for patients with longstanding S. haematobium infection
FGS: praziquantel with gynecological follow-up
Mass Drug Administration (MDA): WHO recommends preventive chemotherapy with praziquantel for all school-age children and at-risk adults in endemic areas, delivered through MDA programs annually or biannually.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Prevention Strategies
There is currently no licensed vaccine for schistosomiasis. Prevention relies on avoiding contaminated freshwater, mass drug administration, snail control, and improved water and sanitation.
Personal Protective Measures (Travelers):
Avoid all freshwater contact in endemic areas: do not swim, wade, bathe, or wash in rivers, lakes, streams, irrigation canals, or dams where schistosomiasis is transmitted
If accidental freshwater exposure occurs, vigorously towel-dry the skin immediately (cercarial penetration takes several minutes)
Water safety: Use only treated, filtered, or heated water for bathing. Water heated to >50°C (122°F) for 5 minutes or held in a tank for >48 hours is safe.
Topical repellents: DEET and niclosamide-based creams have shown some protective effect in studies but are not reliably protective
Note: Saltwater and adequately chlorinated swimming pools are safe
Cercariae cannot penetrate intact rubber/waterproof boots, but exposed skin is vulnerable
Mass Drug Administration (MDA):
WHO recommends preventive chemotherapy with praziquantel for:
Frequency: annually in high-transmission areas (>=50% prevalence); biennially in moderate areas (10-50%)
MDA has been the single most impactful intervention for reducing schistosomiasis morbidity globally
Limitations: MDA does not prevent reinfection and must be sustained
Snail Control:
Molluscicides (niclosamide): Chemical control of snail intermediate hosts in transmission sites
Biological control: Introduction of snail predators or competitor species
Environmental management: Drainage of swampy areas, modification of irrigation channels
Integrated vector management combining multiple approaches is most effective
Water, Sanitation, and Hygiene (WASH):
Provision of safe water supplies reduces the need for freshwater contact
Improved sanitation (latrines, sewage treatment) prevents egg contamination of water bodies
Health education on avoidance of freshwater contact
Vaccine Development:
Sm14 (S. mansoni fatty acid binding protein): Phase 2/3 trials underway in Brazil and Senegal
Sh28GST (Bilhvax): Phase 3 trial completed for S. haematobium
SchistoShield (Sm-p80): Preclinical and Phase 1
A practical vaccine remains several years from licensure
Preparation is the best protection.
Travel Advice
Schistosomiasis is one of the most common parasitic infections acquired by travelers. Even brief freshwater exposure in endemic areas can result in infection.
High-Risk Destinations:
Sub-Saharan Africa: The highest risk region globally. Lake Malawi, Lake Victoria, Lake Tanganyika, the Nile basin (Uganda, Egypt, Sudan), and rivers throughout West, Central, and East Africa are well-documented transmission sites.
Southeast Asia: Philippines (S. japonicum), parts of Laos and Cambodia (S. mekongi)
South America: Brazil (especially northeastern states — Bahia, Minas Gerais, Pernambuco), Suriname, Venezuela
Middle East: Yemen, parts of Iraq
Caribbean: Historically in some islands; risk now minimal in most
Common Exposure Scenarios for Travelers:
Swimming or bathing in Lake Malawi (a very common traveler exposure)
Rafting or kayaking on rivers in East/West Africa
Wading across streams during trekking (East Africa, Madagascar)
Bathing in waterfalls in West Africa or Brazil
Participating in freshwater activities during voluntourism or gap year travel
Pre-Travel Recommendations:
During Travel:
Avoid ALL freshwater contact in endemic areas — swimming, wading, washing, even brief water crossings
If accidental exposure occurs, immediately towel-dry thoroughly
Use treated water (boiled or held >48 hours) for bathing
Ocean swimming and properly maintained swimming pools are safe
Post-Travel:
All travelers with freshwater exposure in endemic areas should be screened for schistosomiasis, even if asymptomatic
Screening should occur at least 8-12 weeks after last exposure (to allow antibody development and egg production)
Testing: serology (antibody detection) is the most sensitive test for travelers; stool/urine microscopy has low sensitivity for light infections
Eosinophilia on routine blood work should prompt evaluation for schistosomiasis in returned travelers
Treatment with praziquantel is simple, safe, and curative
Early treatment prevents all long-term complications
Statistics and geographic data
Epidemiology
Schistosomiasis is one of the most prevalent parasitic diseases globally, with a distribution determined by the presence of suitable freshwater snail hosts and human freshwater contact patterns.
Global Burden:
240 million people infected in 78 countries (WHO estimate)
700 million at risk in endemic areas
~11,700-200,000 deaths annually (GBD 2019: ~11,700; older WHO estimates: ~200,000; primarily from hepatosplenic and urogenital complications)
4.5 million DALYs lost annually (likely underestimated)
Over 90% of the global burden is in sub-Saharan Africa
Second only to malaria among parasitic diseases in terms of socioeconomic impact
Species Distribution:
S. mansoni: Africa (widespread), Middle East (Yemen, Saudi Arabia), South America (Brazil, Venezuela, Suriname), Caribbean (historically)
S. haematobium: Africa (widespread), Middle East (Iraq, Yemen), Corsica (France — newly emerged focus since 2013)
S. japonicum: China (Yangtze River basin — greatly reduced), Philippines (Leyte, Mindanao, others), Indonesia (Sulawesi)
S. mekongi: Laos, Cambodia (Mekong River)
S. intercalatum/guineensis: West and Central Africa (limited foci)
Prevalence Patterns:
Prevalence peaks in children aged 10-14 years (can exceed 80% in high-transmission areas)
Infection intensity (egg counts) also peaks in this age group
Adults develop partial immunity, resulting in lower intensity with age
Urban transmission is increasingly recognized (e.g., Kinshasa, Dar es Salaam)
Notable Epidemiological Developments:
Corsica, France: Autochthonous S. haematobium transmission since 2013 — first known European focus in modern times, linked to hybridization with livestock schistosomes
China: Dramatic reduction in S. japonicum through integrated control (from 12 million infected in 1950s to <30,000 currently), but elimination remains elusive
Dam and irrigation projects: Consistently associated with new or increased schistosomiasis transmission (e.g., Aswan Dam/Egypt, Three Gorges/China)
WHO Control Strategy:
Preventive chemotherapy via MDA with praziquantel
Target: treat >=75% of school-age children in endemic areas
By 2023, >100 million people treated annually through MDA programs
Goal: elimination as a public health problem by 2030 (defined as <1% heavy-intensity infections in all endemic areas)
Climate Change:
Potential expansion of snail habitats into currently non-endemic areas (southern Europe, higher altitudes in Africa)
Changes in rainfall and water management patterns may alter transmission dynamics
Who is most at risk
Risk Factors
Risk factors for schistosomiasis infection and severe disease relate to freshwater exposure patterns, geographic location, and host factors.
Risk Factors for Infection:
Freshwater contact in endemic areas: The essential risk factor. Any skin exposure to cercariae-contaminated freshwater can result in infection.
Geographic location: Living in or traveling to endemic areas with active transmission
Age and water contact patterns: School-age children (5-14 years) have the highest prevalence and intensity in endemic areas due to frequent recreational and domestic water contact
Occupational exposure:
Domestic water use: Washing clothes, bathing, fetching water from contaminated sources
Recreational exposure: Swimming, playing, bathing in contaminated freshwater
Absence of safe water supply: Communities without piped water are dependent on contaminated surface water
Seasonal factors: Transmission may be seasonal in some areas (linked to snail population dynamics and rainfall)
Risk Factors for Severe/Chronic Disease:
Intensity of infection: High worm burden (reflected by high egg counts) is the strongest determinant of organ damage
Duration of infection: Years to decades of untreated infection increase cumulative tissue damage
Reinfection: Repeated reinfection maintains high worm burdens and egg deposition
Species: S. japonicum produces ~10x more eggs than S. mansoni, causing more rapid hepatic fibrosis
Co-infection with hepatitis B or C: Dramatically worsens hepatic schistosomiasis; co-infection accelerates fibrosis and increases mortality from liver disease
Genetic factors: HLA type and immunogenetic variation influence granuloma formation and fibrosis
Nutritional status: Malnutrition increases susceptibility to disease manifestations
HIV co-infection: May alter immune response to schistosome eggs; reduces efficacy of praziquantel
Protective Factors:
Partial immunity develops with age and repeated exposure (adults in endemic areas typically have lower infection intensity than children)
Praziquantel treatment reduces worm burden and morbidity
Safe water supply and improved sanitation eliminate exposure
Health education on avoidance of freshwater contact
Potential complications
Complications
Schistosomiasis complications are driven by the granulomatous immune response to trapped eggs in tissues, leading to progressive fibrosis and organ damage over months to decades.
Hepatosplenic Complications (S. mansoni, S. japonicum):
Periportal (Symmers pipe-stem) fibrosis: The pathognomonic lesion of hepatosplenic schistosomiasis. Granulomatous inflammation around portal tracts leads to characteristic periportal fibrosis visualized on ultrasound. Unlike cirrhosis, hepatocellular function is generally preserved.
Portal hypertension: Progressive periportal fibrosis obstructs portal blood flow, leading to elevated portal pressure, splenomegaly, and portosystemic collateral formation.
Esophageal and gastric varices: The most dangerous complication of portal hypertension. Variceal hemorrhage is a leading cause of death in hepatosplenic schistosomiasis, with mortality of 20-30% per bleeding episode.
Massive splenomegaly: With hypersplenism (pancytopenia) — common in advanced disease.
Ascites: Develops in advanced portal hypertension.
Hepatic decompensation: Uncommon with pure schistosomal fibrosis but occurs when co-infected with hepatitis B or C (synergistic liver damage).
Urogenital Complications (S. haematobium):
Bladder fibrosis and calcification: Progressive thickening and calcification of the bladder wall, visible on imaging. Reduces bladder capacity.
Hydronephrosis and hydroureter: Ureteral egg granulomas cause strictures and obstruction, leading to progressive upper tract dilation and chronic renal failure.
Squamous cell carcinoma of the bladder: S. haematobium is an IARC Group 1 carcinogen. Bladder cancer incidence in high-transmission areas is dramatically elevated. Typically presents at younger ages (40s-50s) compared to non-schistosomal bladder cancer.
Female genital schistosomiasis (FGS): Affects an estimated 56 million women and girls. Cervical and vaginal granulomas ("sandy patches") cause contact bleeding, discharge, dyspareunia, chronic pelvic pain, and infertility. FGS increases HIV acquisition risk by 3-4 fold due to disruption of the genital mucosal barrier.
Male genital involvement: Hematospermia, prostatitis, orchitis, epididymitis. May contribute to infertility.
Neurological Complications (All Species):
Spinal cord schistosomiasis: Most common with S. mansoni. Egg deposition in the spinal cord (usually lower thoracic/conus medullaris) causes granulomatous transverse myelitis. Presents with acute or subacute lower limb weakness, sensory level, and sphincter dysfunction. Requires urgent treatment with corticosteroids and praziquantel.
Cerebral schistosomiasis: More common with S. japonicum (due to smaller egg size crossing the pulmonary filter). Presents with seizures, raised intracranial pressure, focal deficits.
Pulmonary Complications:
Pulmonary hypertension (cor pulmonale): Eggs embolize to pulmonary arterioles, causing granulomatous arteritis and progressive pulmonary hypertension. More common with hepatosplenic disease (portosystemic shunting allows eggs to bypass the liver).
Respiratory symptoms: Cough, dyspnea in advanced pulmonary involvement.
Renal Complications:
Glomerulonephritis: Immune complex deposition in glomeruli (particularly with S. mansoni), leading to nephrotic syndrome.
Chronic kidney disease: From obstructive uropathy (S. haematobium) or glomerulonephritis.
Nutritional and Developmental Impact:
Expected outcomes and recovery
Prognosis and Outcomes
The prognosis for schistosomiasis depends critically on the intensity and duration of infection, the species involved, and access to treatment.
Acute Schistosomiasis (Katayama Syndrome):
Generally good prognosis with appropriate treatment (corticosteroids + praziquantel)
Self-limiting even without treatment in most cases, though recovery may take months
Rarely fatal, but severe cases (particularly with neurological or respiratory involvement) can be life-threatening
Travelers may experience prolonged eosinophilia and fatigue even after treatment
Chronic Schistosomiasis — With Treatment:
Early treatment (before significant fibrosis): Excellent prognosis. Praziquantel eliminates adult worms, stops new egg deposition, and allows resolution of inflammation. Mild hepatic and urinary changes are largely reversible.
Cure rates: 70-100% with single-dose praziquantel
Egg reduction rates: >95%
Reinfection: Common in endemic areas without sustained MDA programs. Repeated treatment reduces cumulative morbidity.
Chronic Schistosomiasis — Without Treatment:
Progressive organ damage over years to decades
Hepatosplenic disease (S. mansoni/japonicum): Portal hypertension, esophageal varices (risk of fatal hemorrhage), hepatosplenomegaly. Note: hepatocellular function is typically preserved (unlike cirrhosis) unless concurrent viral hepatitis is present.
Urogenital disease (S. haematobium): Progressive bladder fibrosis, hydronephrosis, chronic renal failure. Squamous cell carcinoma of the bladder — S. haematobium is a IARC Group 1 carcinogen; bladder cancer incidence is markedly elevated in high-transmission areas.
Neurological Prognosis:
Spinal cord disease: If treated promptly with corticosteroids and praziquantel, significant neurological recovery is possible. Delayed treatment results in permanent paraplegia.
Cerebral disease: Variable outcomes; seizure disorders may persist
Impact on Child Development: In endemic areas, chronic schistosomiasis in children is associated with:
Iron deficiency anemia and malnutrition
Stunted growth and physical development
Impaired cognitive development and reduced school performance
These effects are substantially reversible with treatment and nutritional support
Life Expectancy:
Untreated hepatosplenic schistosomiasis with portal hypertension reduces life expectancy significantly
Treated patients, even with established fibrosis, can have near-normal life expectancy with appropriate portal hypertension management
S. haematobium-related bladder cancer is the major cause of schistosomiasis-attributable mortality
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useGeographic distribution and active outbreaks
Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.
| High risk |
 | South Sudan | High risk |
 | Sudan | High risk |
 | Côte d'Ivoire | High risk |
 | Sierra Leone | High risk |
 | Cameroon | High risk |
 | Niger | High risk |
